Merck’s $3B return to eye disease; J&J’s $1.25B tuck-in; Keytruda challenger steals #ASCO24 show; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

What an action-packed weekend! To stay on top of cancer research, be sure to check out our ASCO coverage and the wrap-up event on Tuesday. Meanwhile, another team will be in San Diego next week to cover the BIO conference. For those of you who will be at Endpoints’ parallel event, see you there!

Merck’s $3B return to eye disease

Merck is launching a return to the lucrative eye disease market in an acquisition for EyeBio that could be worth $3 billion, including $1.3 billion upfront. EyeBio, a Series A-stage biotech, is seeking to begin a pivotal study of…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks